SEC filing · 8-K

Standard Biotools Inc.: Material agreement

Standard BioTools terminated its prior deal and agreed to sell its mass cytometry business to Element Biosystems for $5.5 million in cash.

Filed September 30, 2026

Positive for the company

What happened

On September 30, 2026, Standard BioTools terminated its purchase agreement with Multiplex Bio after accepting a superior proposal.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Standard Biotools Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.